Nona Biosciences Inks Research Partnership With Atossa Therapeutics For Next-gen Breast Cancer Drugs

(RTTNews) - Biotechnology company Nona Biosciences announced Thursday a research collaboration with Atossa Therapeutics Inc. (ATOS). The collaboration leverages Nona's proprietary H2L2 Harbour Mice platform to identify next-generation therapeutic candidates for breast cancer.

Nona Biosciences' proprietary Harbour Mice platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization.

Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development.

To date, Harbour Mice platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.